• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

化脓性汗腺炎的新疗法和新评估工具。

New treatments and new assessment instruments for Hidradenitis suppurativa.

机构信息

Department of Dermatology, University of Michigan, Ann Arbor, Michigan, USA.

European Hidradenitis Suppurativa Foundation e.V., Dessau, Germany.

出版信息

Exp Dermatol. 2022 Sep;31 Suppl 1(Suppl 1):33-39. doi: 10.1111/exd.14609.

DOI:10.1111/exd.14609
PMID:35582833
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9542859/
Abstract

Research interest in Hidradenitis Suppurativa (HS) has grown exponentially over the past decades. Several groups have worked to develop novel scores that address the drawbacks of existing investigator-assessed and patient-reported outcome measures currently used in HS trials, clinical practice and research. In clinical trial settings, the drawbacks of the HiSCR have become apparent; mainly, it is lack of a dynamic measurement of draining tunnels. The newly developed (dichotomous) IHS4 and HASI-R are backed up by adequate validation data and are good contenders to become the new primary outcome measure in HS clinical trials. Patient-reported outcomes, as well as physician reported measures, are being developed by the HIdradenitis SuppuraTiva cORe outcomes set International Collaboration (HISTORIC). For example, the Hidradenitis Suppurativa Quality of Life (HiSQOL) score is a validated measure of HS-specific quality of life and is already being used in many HS trials. Magnitude of pain measurement via a 0-10 numerical rating scale is well-established; however, consensus is still required to ensure consistent administration and interpretation of the instrument. A longitudinal measurement over multiple days rather than at one time point, such as for example the Pain Index could provide increased reliability and reduced recall bias. Ultimately, these newly developed scores and tools can be included in a standardized registry to be used in routine clinical practice.

摘要

过去几十年来,对化脓性汗腺炎(HS)的研究兴趣呈指数级增长。许多研究小组致力于开发新的评分系统,以解决目前在 HS 临床试验、临床实践和研究中使用的现有研究者评估和患者报告的结果测量方法的缺点。在临床试验中,HiSCR 的缺点已经很明显;主要是,它缺乏对引流隧道的动态测量。新开发的(二分法)IHS4 和 HASI-R 有充分的验证数据支持,是成为 HS 临床试验新的主要结局测量指标的有力竞争者。患者报告的结果以及医生报告的测量方法,正在由化脓性汗腺炎核心结局设定国际合作组织(HISTORIC)开发。例如,化脓性汗腺炎生活质量(HiSQOL)评分是一种经过验证的 HS 特异性生活质量测量方法,已经在许多 HS 试验中使用。通过 0-10 数字评分量表对疼痛程度进行测量已经得到了很好的证实;然而,仍然需要达成共识,以确保仪器的一致管理和解释。与仅在一个时间点相比,如疼痛指数,在多个连续日进行纵向测量可以提供更高的可靠性和降低回忆偏倚。最终,这些新开发的评分系统和工具可以被纳入一个标准化的登记系统,以便在常规临床实践中使用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dfe2/9542859/2811fd6c9212/EXD-31-33-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dfe2/9542859/2811fd6c9212/EXD-31-33-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dfe2/9542859/2811fd6c9212/EXD-31-33-g001.jpg

相似文献

1
New treatments and new assessment instruments for Hidradenitis suppurativa.化脓性汗腺炎的新疗法和新评估工具。
Exp Dermatol. 2022 Sep;31 Suppl 1(Suppl 1):33-39. doi: 10.1111/exd.14609.
2
Inter-rater agreement and reliability of outcome measurement instruments and staging systems used in hidradenitis suppurativa.化脓性汗腺炎结局评估工具和分期系统的评价者间信度和可靠性。
Br J Dermatol. 2019 Sep;181(3):483-491. doi: 10.1111/bjd.17716. Epub 2019 Jun 6.
3
Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment.评估化脓性汗腺炎临床应答(HiSCR)作为化脓性汗腺炎治疗的临床终点的有效性、反应性和有意义性。
Br J Dermatol. 2014 Dec;171(6):1434-42. doi: 10.1111/bjd.13270. Epub 2014 Nov 11.
4
Validation of the Hidradenitis Suppurativa Investigator Global Assessment: A Novel Hidradenitis Suppurativa-Specific Investigator Global Assessment for Use in Interventional Trials.化脓性汗腺炎研究者全球评估量表的验证:一种新型化脓性汗腺炎特异性研究者全球评估量表,用于干预性试验。
JAMA Dermatol. 2023 Jun 1;159(6):606-612. doi: 10.1001/jamadermatol.2023.0797.
5
Clinical response rates, placebo response rates, and significantly associated covariates are dependent on choice of outcome measure in hidradenitis suppurativa: A post hoc analysis of PIONEER 1 and 2 individual patient data.临床缓解率、安慰剂缓解率和显著相关的协变量取决于化脓性汗腺炎的结局测量选择:PIONEER 1 和 2 个体患者数据的事后分析。
J Am Acad Dermatol. 2020 May;82(5):1150-1157. doi: 10.1016/j.jaad.2019.12.044. Epub 2019 Dec 24.
6
Development and validation of IHS4-55, an IHS4 dichotomous outcome to assess treatment effect for hidradenitis suppurativa.IHS4 - 55的开发与验证,这是一种用于评估化脓性汗腺炎治疗效果的IHS4二分结果。
J Eur Acad Dermatol Venereol. 2023 Feb;37(2):395-401. doi: 10.1111/jdv.18632. Epub 2022 Oct 19.
7
Convergent Validity of Suffering and Quality of Life as Measured by The Hidradenitis Suppurativa Quality of Life.化脓性汗腺炎生活质量量表所测量的痛苦与生活质量的收敛效度
J Eur Acad Dermatol Venereol. 2021 Jul;35(7):1577-1581. doi: 10.1111/jdv.17148. Epub 2021 Mar 3.
8
Development of core outcome sets in hidradenitis suppurativa: systematic review of outcome measure instruments to inform the process.化脓性汗腺炎核心结局集的制定:系统评价结局测量工具以提供信息。
Br J Dermatol. 2016 Aug;175(2):263-72. doi: 10.1111/bjd.14475. Epub 2016 May 2.
9
External Validation of the IHS4-55 in a European Antibiotic-Treated Hidradenitis Suppurativa Cohort.IHS4-55 在欧洲抗生素治疗的化脓性汗腺炎队列中的外部验证。
Dermatology. 2023;239(3):362-367. doi: 10.1159/000528968. Epub 2023 Jan 30.
10
Development and initial validation of the HS-IGA: a novel hidradenitis suppurativa-specific investigator global assessment for use in interventional trials.HS-IGA 的制定和初步验证:一种新型的化脓性汗腺炎特异性研究者整体评估,用于干预性试验。
Br J Dermatol. 2022 Aug;187(2):203-210. doi: 10.1111/bjd.21236. Epub 2022 May 22.

引用本文的文献

1
Towards a Paradigm Shift in Delivering Hidradenitis Suppurativa Care: a Narrative Review.朝着化脓性汗腺炎护理的范式转变:一项叙述性综述
Dermatol Ther (Heidelb). 2025 Jun 29. doi: 10.1007/s13555-025-01462-7.
2
Nursing Knowledge and Skills in Hidradenitis Suppurativa: A Multi-Centre Exploratory Study.化脓性汗腺炎的护理知识与技能:一项多中心探索性研究
Nurs Rep. 2025 Jan 26;15(2):40. doi: 10.3390/nursrep15020040.
3
Hidradenitis suppurativa with and without draining tunnels: A real-world study characterizing differences in treatment and disease burden.

本文引用的文献

1
Development and validation of IHS4-55, an IHS4 dichotomous outcome to assess treatment effect for hidradenitis suppurativa.IHS4 - 55的开发与验证,这是一种用于评估化脓性汗腺炎治疗效果的IHS4二分结果。
J Eur Acad Dermatol Venereol. 2023 Feb;37(2):395-401. doi: 10.1111/jdv.18632. Epub 2022 Oct 19.
2
Identification of clinical features affecting diagnostic delay in paediatric hidradenitis suppurativa: results from a multicentre observational study.影响儿童化脓性汗腺炎诊断延迟的临床特征识别:一项多中心观察性研究的结果
Br J Dermatol. 2022 Sep;187(3):428-430. doi: 10.1111/bjd.21247. Epub 2022 May 28.
3
Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa: A Phase 2, Double-blind, Placebo-Controlled Randomized Clinical Trial.
伴有和不伴有引流通道的化脓性汗腺炎:一项描述治疗差异和疾病负担的真实世界研究。
J Eur Acad Dermatol Venereol. 2025 Aug;39(8):1431-1441. doi: 10.1111/jdv.20550. Epub 2025 Feb 4.
4
European S2k guidelines for hidradenitis suppurativa/acne inversa part 2: Treatment.欧洲化脓性汗腺炎/反向性痤疮S2k指南第2部分:治疗
J Eur Acad Dermatol Venereol. 2025 May;39(5):899-941. doi: 10.1111/jdv.20472. Epub 2024 Dec 19.
5
Secukinumab efficacy in patients with hidradenitis suppurativa assessed by the International Hidradenitis Suppurativa Severity Score System (IHS4): A post hoc analysis of the SUNSHINE and SUNRISE trials.依奇珠单抗在化脓性汗腺炎患者中的疗效通过国际化脓性汗腺炎严重程度评分系统(IHS4)评估:SUNSHINE和SUNRISE试验的事后分析
J Eur Acad Dermatol Venereol. 2025 Aug;39(8):1421-1430. doi: 10.1111/jdv.20369. Epub 2024 Oct 19.
6
Essentials of hidradenitis suppurativa: a comprehensive review of diagnostic and treatment perspectives.化脓性汗腺炎要点:诊断与治疗观点的全面综述
Ann Med Surg (Lond). 2024 Jul 1;86(9):5304-5313. doi: 10.1097/MS9.0000000000002345. eCollection 2024 Sep.
7
Longitudinal remote monitoring of hidradenitis suppurativa: a pilot study.汗腺炎的纵向远程监测:一项试点研究。
Br J Dermatol. 2024 Jan 23;190(2):274-276. doi: 10.1093/bjd/ljad385.
8
Requirements for Brazilian Outpatient Centers of Excellence in Hidradenitis Suppurativa: Consensus Co-Creative Study.巴西化脓性汗腺炎卓越门诊中心的要求:共识共创研究。
Clin Cosmet Investig Dermatol. 2023 Aug 4;16:2029-2044. doi: 10.2147/CCID.S420750. eCollection 2023.
9
Overview and comparison of the clinical scores in hidradenitis suppurativa: A real-life clinical data.化脓性汗腺炎临床评分的概述与比较:真实临床数据
Front Med (Lausanne). 2023 Apr 17;10:1145152. doi: 10.3389/fmed.2023.1145152. eCollection 2023.
10
External Validation of the IHS4-55 in a European Antibiotic-Treated Hidradenitis Suppurativa Cohort.IHS4-55 在欧洲抗生素治疗的化脓性汗腺炎队列中的外部验证。
Dermatology. 2023;239(3):362-367. doi: 10.1159/000528968. Epub 2023 Jan 30.
比美吉珠单抗治疗中重度化脓性汗腺炎的疗效和安全性:一项 2 期、双盲、安慰剂对照随机临床试验。
JAMA Dermatol. 2021 Nov 1;157(11):1279-1288. doi: 10.1001/jamadermatol.2021.2905.
4
Efficacy and Safety of Adalimumab in Conjunction With Surgery in Moderate to Severe Hidradenitis Suppurativa: The SHARPS Randomized Clinical Trial.阿达木单抗联合手术治疗中重度化脓性汗腺炎的疗效和安全性:SHARPS 随机临床试验。
JAMA Surg. 2021 Nov 1;156(11):1001-1009. doi: 10.1001/jamasurg.2021.3655.
5
Real-world effectiveness of adalimumab in patients with moderate-to-severe hidradenitis suppurativa: the 1-year SOLACE study.阿达木单抗治疗中重度化脓性汗腺炎患者的真实世界疗效:为期 1 年的 SOLACE 研究。
J Eur Acad Dermatol Venereol. 2021 Dec;35(12):2431-2439. doi: 10.1111/jdv.17598. Epub 2021 Aug 25.
6
Hidradenitis suppurativa-specific, patient-reported outcome measures.化脓性汗腺炎特异性的患者报告结局指标。
J Eur Acad Dermatol Venereol. 2021 Jul;35(7):1420-1421. doi: 10.1111/jdv.17306.
7
Pain Index: a new prospective hidradenitis suppurativa patient-reported outcome measure instrument.疼痛指数:一种新的前瞻性化脓性汗腺炎患者报告结局测量工具。
Br J Dermatol. 2021 Jun;184(6):1203-1204. doi: 10.1111/bjd.19798. Epub 2021 Mar 2.
8
The efficacy and tolerability of tetracyclines and clindamycin plus rifampicin for the treatment of hidradenitis suppurativa: Results of a prospective European cohort study.四环素类药物和克林霉素联合利福平治疗化脓性汗腺炎的疗效和耐受性:一项前瞻性欧洲队列研究的结果。
J Am Acad Dermatol. 2021 Aug;85(2):369-378. doi: 10.1016/j.jaad.2020.12.089. Epub 2021 Jan 20.
9
Prevalence of Neuropathic Pain and Related Characteristics in Hidradenitis Suppurativa: A Cross-Sectional Study.化脓性汗腺炎中神经性疼痛的患病率及相关特征:一项横断面研究
J Clin Med. 2020 Dec 15;9(12):4046. doi: 10.3390/jcm9124046.
10
Physical symptoms and psychosocial problems associated with hidradenitis suppurativa: correlation with Hurley stage.与化脓性汗腺炎相关的躯体症状和心理社会问题:与 Hurley 分期的相关性。
Dermatol Online J. 2020 Sep 15;26(9):13030/qt4rm8w7kn.